Key facts
- This page summarizes Kraus al's Form 4 filing for Cytosorbents Corp (CTSO).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 08 Feb 2023, 05:03.
Kraus al - 06 Feb 2023 Form 4 Insider Report for Cytosorbents Corp (CTSO)
- Reporting relationship
- Director
- Issuer ticker
- CTSO
- Reported as of
- 06 Feb 2023
- Net transaction value
- +$31,800
- SEC form
- 4
- Accepted by SEC
- 08 Feb 2023, 05:03:33 UTC
- Prior SEC filing
- 12 Aug 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Kathleen P. Bloch attorney-in-fact for Al Kraus
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Kraus al filed Form 4 for Cytosorbents Corp (CTSO) on 08 Feb 2023.
Change
- Previous filing in this sequence was filed on 12 Aug 2022.
- Current net transaction value: +$31,800.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CTSO
transaction
Common Stock
Options Exercise
- Transaction value
- $31,800
- Shares
- +12,000
- Change %
- +9.2%
- Price
- $2.65
- Shares after
- 142,046
- Date
- 06 Feb 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CTSO
transaction
Derivative
Stock Option (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -12,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 06 Feb 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 12,000
- Exercise price
- $2.65
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Includes: (i) the following RSUs that will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Company") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 55,000 RSUs granted on April 8, 2015, (b) 5,000 RSUs granted on June 7, 2016, (c) 6,000 RSUs granted on February 24, 2017 and (d) 3,300 RSUs granted on March 15, 2018; and (ii) 72,746 shares of common stock owned by the reporting person.
Footnote F2
The stock options were granted to the reporting person on February 6, 2013 and were exercisable on the date of grant.